AOD-9604.
A fat-mobilization peptide for stubborn fat — without affecting appetite or blood sugar.
Pricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients who don't qualify for GLP-1 medications
- Patients struggling with fat-loss plateaus
- Patients wanting a gentler, steady weight-loss peptide
- Patients carrying stubborn fat in specific areas
- Patients wanting a long-term-tolerable option
This isn't for you if
Generally well tolerated. Not appropriate during pregnancy or with active malignancy.
AOD-9604
AOD-9604 is a peptide fragment that activates fat-mobilization pathways. Unlike GLP-1 medications, it does not affect appetite or blood sugar — making it an option for patients who don't qualify for or tolerate incretin therapy.
Mechanism and fit.
AOD-9604 stimulates the breakdown of stored fat, particularly in stubborn areas (hips, thighs, abdomen). It is often used during weight-loss plateaus or as a gentler, steadier weight-management option.
Who this is typically for.
- Patients who don't qualify for GLP-1 medications
- Patients struggling with fat-loss plateaus
- Patients wanting a gentler, steady weight-loss peptide
- Patients carrying stubborn fat in specific areas
- Patients wanting a long-term-tolerable option
What patients
most often ask.
How is AOD different from GLP-1 medications?
AOD-9604 acts on fat-mobilization pathways without affecting appetite or blood sugar. GLP-1 medications work on appetite, gastric emptying, and insulin. They address different problems and are sometimes used together.
Is it safe long-term?
AOD-9604 is well tolerated in physician-supervised use. Your provider will determine duration based on goals and response.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients who don't qualify for GLP-1 medications</li><li>Patients struggling with fat-loss plateaus</li><li>Patients wanting a gentler, steady weight-loss peptide</li><li>Patients carrying stubborn fat in specific areas</li><li>Patients wanting a long-term-tolerable option</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingDaily by injection.
- Typical duration8–12 weeks per cycle.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering AOD-9604, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.